PDF下载 ( 1548 KB)
Research advances in primary biliary cholangitis
-
摘要:
原发性胆汁性胆管炎是一种慢性肝内胆汁淤积性疾病,文献报道其发病率和患病率不断提高。通过检查血清抗线粒体抗体M2亚型等特异性抗体或肝组织病理学检查可确定诊断。熊去氧胆酸是治疗本病的主要药物,但对熊去氧胆酸生化学应答欠佳者疾病进展快,目前尚无统一有效的治疗手段。加用布地奈德、非诺贝特、苯扎贝特或奥贝胆酸可能对部分患者有效,但仍需进一步临床研究验证。
Abstract:Primary biliary cholangitis is a chronic intrahepatic cholestatic liver disease and has increasing incidence and prevalence rates,as is reported in the literature. Examination of specific antibodies including serum anti- mitochondrial antibody subtype M2 and liver histopathological examination help to make a definite diagnosis of this disease. Ursodeoxycholic acid( UDCA) is often used for the treatment of this disease,but patients with an unsatisfactory biochemical response to UDCA tend to have rapid disease progression. At present,there are no effective treatment methods for such patients. The addition of budesonide,fenofibrate,bezafibrate,or obeticholic acid may be effective in these patients,but this needs to be verified by further clinical studies.
-
Key words:
- liver cirrhosis /
- biliary /
- diagnosis
-
[1]CHUANG N,GROSS RG,ODIN JA.Update on the epidemiology of primary biliary cirrhosis[J].Expert Rev Gastroenterol Hepatol,2011,5(5):583-590. [2]SAKUGAWA H,NAKASONE H,NAKAYOSHI T,et al.Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa,Japan[J].Hepatol Res,2003,26(4):330-336. [3]JIANG XH,ZHONG RQ,FAN XY,et al.Characterization of M2 antibodies in asymptomatic Chinese population[J].World J Gastroenterol,2003,9(9):2128-2131. [4]LIU H,LIU Y,WANG L,et al.Prevalence of primary biliary cirrhosis in adults referring hospital for annual health checkup in Southern China[J].BMC Gastroenterol,2010,10:100. [5]HE YQ,LIU Q,YE ZX,et al.11024 cases of anti-mitochondrial antibody type M2 screening results[J].Mod Med J China,2015,11(17):1-3.(in Chinese)何宇晴,刘强,叶震璇,等.M2型线粒体抗体筛查11024例结果分析[J].中国现代医药杂志,2015,11(17):1-3. [6]HIRSCHFIELD GM,LIU X,XU C,et al.Primary biliary cirrhosis associated with HLA,IL12A,and IL12RB2 variants[J].N Engl J Med,2009,360(24):2544-2555. [7]CORDELL HJ,HAN Y,MELLS GF,et al.International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways[J].Nat Commun,2015,6:8019. [8]NAKAMURA M,NISHIDA N,KAWASHIMA M,et al.Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population[J].Am J Hum Genet,2012,91(4):721-728. [9]DONG M,LI J,TANG R,et al.Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population[J].Clin Rev Allergy Immunol,2015,48(2-3):316-321. [10]BOGDANOS DP,KOMOROWSKI L.Disease-specific autoantibodies in primary biliary cirrhosis[J].Clin Chim Acta,2011,412(7-8):502-512. [11]HU SL,ZHAO FR,HU Q,et al.Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis[J].PLo S One,2014,9(7):e101916. [12]LIU H,NORMAN GL,SHUMS Z,et al.PBC Screen:an Ig G/Ig A dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis[J].J Autoimmun,2010,35(4):436-442. [13]WENDUM D,BOLLE PY,BEDOSSA P,et al.Primary biliary cirrhosis:proposal for a new simple histological scoring system[J].Liver Int,2015,35(2):652-659. [14]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识[J].临床肝胆病杂志,2015,31(12):1980-1988. [15]LAMMERS WJ,HIRSCHFIELD GM,CORPECHOT C,et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology,2015,149(7):1804-1812. [16]CARBONE M,SHARP SJ,FLACK S,et al.The UK-PBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J].Hepatology,2016,63(3):930-950. [17]RAUTIAINEN H,KRKKINEN P,KARVONEN AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology,2005,41(4):747-752. [18]HEMPFLING W,GRUNHAGE F,DILGER K,et al.Pharmacokinetics and pharmacodynamic action of budesonide in early-and lat-stage primary biliary cirrhosis[J].Hepatology,2003,38(1):196-202. [19]ZHANG Y,LI S,HE L,et al.Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis[J].Drug Des Devel Ther,2015,9:2757-2766. [20]YIN Q,LI J,XIA Y,et al.Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhsis[J].Drug Des Devel Ther,2015,9:5407-5419. [21]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761. [22]CAREY EJ,ALI AH,LINDOR KD.Primary biliary cirrhosis[J].Lancet,2015,386(10003):1565-1575. [23]CARBONE M,NEUBERGER J.Liver transplantation in PBC and PSC:indications and disease recurrence[J].Clin Res Hepatol Gastroenterol,2011,35(6-7):446-454. [24]BOSCH A,DUMORTIER J,MAUCORT-BOULCH D,et al.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis[J].J Hepatol,2015,63(6):1449-1458. -
本文二维码
计量
- 文章访问数: 2293
- HTML全文浏览量: 39
- PDF下载量: 553
- 被引次数: 0
下载:
